L. Fein

发表

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.

E. Cazap, L. Fein, D. Lewi, 1997, Seminars in oncology.

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.

J. Jassem, X. Pivot, H. Chung, 2009, European journal of cancer.

Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.

L. Dirix, M. Kaufmann, S. Jones, 2000, Clinical breast cancer.

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.

L. Dirix, M. Kaufmann, S. Jones, 2000, European journal of cancer.

Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.

L. Fein, D. Lewi, S. Jovtis, 2001, Seminars in oncology.

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.

Y. Park, D. Ye, B. Alekseev, 2017 .

Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATIT

B. Alekseev, K. Fizazi, K. Chi, 2019, European urology.

Gallbladder cancer: surgical results after cholecystectomy in 25 patients with lamina propria invasion and 26 patients with muscular layer invasion.

L. Fein, S. Pezzotto, G. Celoria, 2006, Journal of hepato-biliary-pancreatic surgery.

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

H. Gómez, Bing-he Xu, M. Campone, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.

A. Wozniak, L. Krug, J. Bauman, 2014, Lung cancer.

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

H. Gómez, C. Barrios, G. Werutsky, 2016, Clinical breast cancer.

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

L. Dirix, M. Kaufmann, Stephen E. Jones, 1999 .

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.

M. Campone, J. Jassem, L. Vahdat, 2012, Breast.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Yan-Shen Shan, Paul Ross, Daniel Palmer, 2016, The Lancet.

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.

M. Piccart, S. Lakhani, K. Gelmon, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

D. Ye, B. Alekseev, K. Fizazi, 2019, The Lancet. Oncology.

Phase II trial of gemcitabine (GEM), 5-Fluoruracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer (PC)

L. Fein, D. Lewi, S. Jovtis, 1999 .

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)

B. Rapoport, L. Fein, S. Arora, 2015, Supportive Care in Cancer.

Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

Y. Park, D. Ye, B. Alekseev, 2017, The New England journal of medicine.

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

L. Dirix, M. Kaufmann, Stephen E. Jones, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)

Mano, E. Perez, H. Gómez, 2013 .

Planning cancer control in Latin America and the Caribbean.

Richard Sullivan, Eduardo Cazap, Eduardo Rosenblatt, 2013, The Lancet. Oncology.

Phase II trial of continuous once‐daily dosing of sunitinib as first‐line treatment in patients with metastatic renal cell carcinoma

C. Barrios, Se-Hoon Lee, Jin-Hwang Liu, 2012, Cancer.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).

D. Ye, K. Fizazi, K. Chi, 2019, Journal of Clinical Oncology.

Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.

Y. Park, B. Alekseev, K. Fizazi, 2018 .

Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.

J. R. Pereira, M. Orlando, G. Schwartsmann, 2007, Lung cancer.

Paclitaxel in platinum-resistant ovarian cancer patients

E. Cazap, L. Fein, D. Lewi, 1997 .

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

M. Piccart, W. Gradishar, J. Robertson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract PD1-08: Oral paclitaxel and encequidar (oPac+E) versus IV paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (study KX-ORAX-001): Progression free survival (PFS) and overall survival (OS) updates

H. Rugo, Hui Wang, D. Cutler, 2021 .

Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.

M. Campone, J. Jassem, L. Vahdat, 2009 .

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5‐fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

L. Fein, J. Block, R. Chacón, 1999, Cancer.

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

H. Rugo, L. Fein, R. Kowalyszyn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.

C. Obasaju, C. Russell, L. Hart, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

J. Baselga, B. Naume, C. Criscitiello, 2018, European journal of cancer.

VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

N. Loman, O. Johannsson, A. Eisen, 2022, Annals of Oncology.

LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

M. Burotto, R. Motzer, T. Powles, 2022, Annals of Oncology.

L. Fein, R. Kowalyszyn, M. Varela, 2022, JCO global oncology.

Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.

A. Buzaid, L. Fein, G. Lerzo, 2010, Clinical colorectal cancer.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

G. Hortobagyi, H. Gómez, Bing-he Xu, 2010, Breast Cancer Research and Treatment.

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

M. Burotto, R. Motzer, T. Powles, 2023, The New England journal of medicine.

LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO).

B. Alekseev, K. Chi, N. Tran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Uracil/tegafur plus oral calcium folinate in advanced breast cancer.

L. Fein, G. Lerzo, E. Richardet, 1999, Oncology.

Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

H. Gómez, C. Barrios, G. Werutsky, 2013 .

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

P. Neven, D. Yee, K. Blackwell, 2011 .

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

L. Fein, M. Mano, N. Lazaretti, 2023, Clinical Drug Investigation.

Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.

Y. Park, B. Alekseev, K. Fizazi, 2018 .

Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.

Y. Park, A. Bjartell, D. Olmos, 2018 .

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Joon-Oh Park, K. Rau, C. Sternberg, 2016, The Lancet.

7122 Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results

M. Brown, C. Barrios, Se-Hoon Lee, 2009 .

Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.

C. Obasaju, A. Seidman, M. Orlando, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.